Northwest & Ethical Investments L.P. Lowers Position in United Therapeutics Co. (NASDAQ:UTHR)

Northwest & Ethical Investments L.P. decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 17.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 3,238 shares of the biotechnology company’s stock after selling 679 shares during the period. Northwest & Ethical Investments L.P.’s holdings in United Therapeutics were worth $1,160,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in United Therapeutics during the second quarter worth about $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the 2nd quarter worth about $33,000. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on UTHR shares. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

Insider Buying and Selling at United Therapeutics

In other news, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 127,227 shares of company stock valued at $47,398,820 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 2.0 %

Shares of UTHR stock opened at $370.49 on Friday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a market capitalization of $16.54 billion, a P/E ratio of 16.27, a PEG ratio of 1.10 and a beta of 0.56. The firm’s 50 day moving average is $367.42 and its 200 day moving average is $334.45.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.